Bi-Specific MAbS Global Market Report 2024

Bispecific monoclonal antibodies (BsAbs) feature dual binding sites, strategically designed to target two distinct antigens or epitopes. Unsuch as traditional monoclonal antibodies (MoAbs), BsAbs offer diverse therapeutic applications, making them invaluable in treating various diseases and advancing tumor immunotherapy.

Prominent examples of bispecific monoclonal antibodies include catumaxomab (utilized for malignant ascites treatment), blinatumomab, duligotumab, and SAR 156597. Catumaxomab, a rat-mouse hybrid monoclonal antibody, addresses malignant ascites linked to metastasizing cancer. These innovative antibodies find application in both in vivo and in vitro settings, contributing to the treatment of conditions such as cancer, autoimmune diseases, inflammatory diseases, infectious diseases, and microbial diseases. Hospitals, research institutes, and other healthcare entities leverage bispecific monoclonal antibodies to enhance therapeutic interventions and advance medical research.

The bi-specific MAbs or bispecific monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides bi-specific MAbs or bispecific monoclonal antibodies market statistics, including bi-specific MAbs or bispecific monoclonal antibodies industry global market size, regional shares, competitors with a bi-specific MAbs or bispecific monoclonal antibodies market share, detailed bi-specific MAbs or bispecific monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the bi-specific MAbs or bispecific monoclonal antibodies industry. This bi-specific MAbs or bispecific monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bi-specific mabs market size has grown rapidly in recent years. It will grow from $8.81 billion in 2023 to $10.25 billion in 2024 at a compound annual growth rate (CAGR) of 16.3%. The expansion observed during the historical period can be ascribed to a surge in healthcare spending, heightened financial support, and proactive government initiatives.

The bi-specific mabs market size is expected to see rapid growth in the next few years. It will grow to $16.9 billion in 2028 at a compound annual growth rate (CAGR) of 13.3%. The anticipated growth in the forecast period is driven by a rising prevalence of cancer, a growing aging population, and an upswing in chronic diseases. Key trends expected in this period encompass a strong emphasis on technological advancements, continuous product innovation, a focus on artificial intelligence integration, investments in targeted and combination therapies, and the establishment of strategic partnerships.

The anticipated rise in cancer and other chronic diseases is poised to significantly bolster the growth of the bispecific monoclonal antibodies (MAbs) market in the foreseeable future. Bispecific monoclonal antibodies are tailored for treating a spectrum of conditions including various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Distinguished by their ability to target multiple tumor antigens, these antibodies are considered more efficacious than conventional monoclonal antibodies (moAbs) in impeding cancer progression. For instance, the American Cancer Society (ACS) projected an estimated 609,820 cancer-related deaths in the USA in 2023, accentuating the increasing need for bi-specific MAbs to effectively combat chronic diseases, notably cancer.

Government initiatives geared towards healthcare research and development are poised to propel the growth of the bispecific MAbs market. These initiatives encompass specific actions, policies, or programs undertaken by governmental bodies to address healthcare challenges, achieve defined objectives, or instigate positive societal changes. An illustrative example involves the collaboration between the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services (HHS), and Regeneron Pharmaceuticals Inc., a US-based science and technology company. Their collaboration under the U.S. Department of Health and Human Services' 'Project NextGen' aims to develop a next-generation monoclonal antibody therapy for preventing SARS-CoV-2 infection. BARDA's commitment to fund up to 70% of Regeneron's clinical development expenses for this therapy, amounting to an estimated contract value of approximately $326 million, exemplifies governmental support for healthcare research and development. Such initiatives drive advancements and contribute to the growth of the bispecific MAbs market.

Companies within the Bi-Specific MAbS market are increasingly engaging in strategic initiatives, particularly collaborations and partnerships, aimed at expanding their product portfolios and global reach. These collaborations represent cooperative ventures between multiple organizations to achieve shared objectives. For instance, in October 2022, Gilead Sciences, a US-based biopharmaceutical firm, partnered with MacroGenics, another US-based biopharmaceutical company, in an exclusive collaboration to develop MGD024, a bispecific antibody targeting CD123 and CD3. This initiative, utilizing MacroGenics' DART platform, includes two additional bispecific research programs. Gilead secured an exclusive option to license MGD024, designed to address various hematologic malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024's unique design aims to mitigate cytokine-release syndrome (CRS) and facilitate intermittent dosing, potentially enhancing treatment convenience and improving clinical outcomes for AML and MDS patients.

Key players in the Bi-Specific MAbS market are leveraging advanced technologies, particularly bispecific monoclonal antibodies, to gain a competitive edge. These artificial proteins have the capability to simultaneously bind to two different types of antigens, targeting specific molecules on cell surfaces. For instance, in September 2021, Amgen, a US-based biopharmaceutical company, collaborated with Boehringer Ingelheim, a Germany-based pharmaceutical company, on a Phase II-ready project. Encouraging clinicians to transition to bispecific mAbs would require substantial improvements in efficacy or safety. Alternative strategies, such as initiating treatment at an earlier disease stage, modifying administration methods, or adjusting treatment frequency, could be viable but necessitate strategic planning from developers. Bispecific mAbs have the potential not only to outperform competitors but also to potentially impact the market share of CAR-T cell therapies, especially in the relapsed or refractory multiple myeloma segment.

In March 2021, Takeda Pharmaceutical Company Limited, a prominent pharmaceutical company based in Japan, successfully acquired Maverick Therapeutics for an undisclosed sum. This strategic acquisition positions Takeda to advance its capabilities in bispecific antibody technology. The synergy between the two entities is expected to enhance resources and leverage accumulated expertise, thereby accelerating the development of Takeda's T-cell engager platform and expanding its pipeline of innovative bispecific immunotherapies. Maverick Therapeutics, a U.S.-based company specializing in biospecific monoclonal antibodies, brings valuable assets and knowledge to further strengthen Takeda's position in the evolving landscape of immunotherapy.

Major companies operating in the bi-specific mabs market report are F. Hoffmann-La Roche AG, Amgen Inc., Johnson & Johnson, Innovent Biologics, Sino Biological Inc., Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, Merck & Co Inc., Eli Lilly Company Inc., AbbVie Inc., Bayer AG, Pfizer Inc., Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, Enteris BioPharma, BioMarin Pharmaceuticals, Parexel, Hikma Pharmaceuticals PLC, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa

North America was the largest region in the bi-specific MAbS market in 2023. The regions covered in the bi-specific mabs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the bi-specific mabs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of trifunctional antibodies, chemically linked Fabs, and bispecific T cell engagers. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bi-Specific MAbS Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bi-specific MAbS market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for bi-specific MAbS? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bi-specific MAbS market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Catumaxomab (Removab); Blinatumomab; Duligotumab; Emicizumab; Amivantamab; Faricimab; Teclistamab
• 2) By Product Type: In Vivo; In Vitro
• 3) By Indication: Cancer; Hemophilia A; Ophthalmic
• 4) By End Use: Hospitals; Research Institutes; Other End-Users
• Companies Mentioned: F. Hoffmann-La Roche AG; Amgen Inc; Johnson & Johnson; Innovent Biologics; Sino Biological Inc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.